Alters Bioscience

Alters Bioscience is a clinical-stage biopharmaceutical company focused on developing next-generation small molecule drugs for autoimmune and inflammatory diseases. The company's core strategy involves targeting validated pathways like TYK2 and JAK1 with highly selective inhibitors to achieve superior safety and efficacy profiles. Its lead candidate, ALT-001, is a potent and selective TYK2 inhibitor currently in Phase 2 clinical development for plaque psoriasis. Alters Bioscience was founded by industry veterans with extensive experience in global drug R&D and is backed by prominent venture capital firms. The company maintains research and development facilities in Beijing and Shanghai to support its growing pipeline of immunology-focused therapeutics.